The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Co‐occurring conditions associated with FMR1 gene variations: Findings from a national parent survey
Abstract
Parents enrolling in a national survey of families of children with fragile X (FX) reported whether each of their children had been diagnosed or treated for developmental delay or eight conditions frequently associated with FX: attention problems, hyperactivity, aggressiveness, self‐injury, autism, seizures, anxiety, or depression. This article reports results for 976 full mutation males, 259 full mutation females, 57 premutation males, and 199 premutation females. Co‐occurring conditions were frequently reported for all FMR1 gene variations. The number of co‐occurring conditions experienced was strongly associated with parent reports of their child's ability to learn, adaptability, and quality of life. Most individuals with the full mutation experienced multiple co‐occurring conditions, with a modal number of 4 for males and 2 for females. Most (>80%) full mutation males and females had been diagnosed or treated for attention problems. Premutation males, when compared with a matched group of non‐FX males, were more likely to have been diagnosed or treated for developmental delay, attention problems, aggression, seizures, autism, and anxiety. Premutation females were more likely to have been diagnosed or treated for attention problems, anxiety, depression, and developmental delay. Clusters of conditions were identified, seeming to occur in an additive fashion. Self‐injury, autism, and seizures rarely occurred in isolation, but were more likely in individuals who also had problems with attention, anxiety, and hyperactivity. The findings provide a reference point for future studies on the prevalence and nature of co‐occurring conditions in FX; suggest the possibility that certain conditions cluster together; provide evidence that male and female carriers experience elevated rates of co‐occurring conditions compared with matched groups of non‐carrier children; and emphasize the importance of including an assessment of co‐occurring conditions in any clinical evaluation of individuals with abnormal variation in the FMR1 gene. © 2008 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Verkerk, A. J. M. H., Pieretti, M., Sutcliffe, J. S., Fu, Y.-H., Kuhl, D. P. A., Pizzuti, A., Reiner, O., Richards, S., Victoria, M. F., Zhang, F., et al. (1991) · Cell · doi:10.1016/0092-8674(91)90397-h · Cited by 3,481
Fragile X Genotype Characterized by an Unstable Region of DNA
Yu, S., Pritchard, M., Kremer, E., Lynch, M., Nancarrow, J., Baker, E., Holman, K., Mulley, J. C., Warren, S. T., Schlessinger, D., et al. (1991) · Science · doi:10.1126/science.252.5009.1179 · Cited by 794
The epidemiology of autistic spectrum disorders: is the prevalence rising?
Wing, L., & Potter, D. (2002) · Mental Retardation and Developmental Disabilities Research Reviews · doi:10.1002/mrdd.10029 · Cited by 623
The Fragile-X Premutation: A Maturing Perspective
Hagerman, P. J., & Hagerman, R. J. (2004) · The American Journal of Human Genetics · doi:10.1086/386296 · Cited by 520
Association of FMR1 repeat size with ovarian dysfunction
Sullivan, A. K., Marcus, M., Epstein, M. P., Allen, E. G., Anido, A. E., Paquin, J. J., Yadav-Shah, M., & Sherman, S. L. (2005) · Human Reproduction · doi:10.1093/humrep/deh635 · Cited by 498
The epidemiology of attention‐deficit/hyperactivity disorder (ADHD): A public health view
Rowland, A. S., Lesesne, C. A., & Abramowitz, A. J. (2002) · Mental Retardation and Developmental Disabilities Research Reviews · doi:10.1002/mrdd.10036 · Cited by 495
A PEDIGREE OF MENTAL DEFECT SHOWING SEX-LINKAGE
Martin, J. P., & Bell, J. (1943) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.6.3-4.154 · Cited by 481
Premature ovarian failure in the fragile X syndrome
Sherman, S. L. (2000) · American Journal of Medical Genetics · doi:10.1002/1096-8628(200023)97:3<189::aid-ajmg1036>3.0.co;2-j · Cited by 437
Autism Spectrum Phenotype in Males and Females with Fragile X Full Mutation and Premutation
Clifford, S., Dissanayake, C., Bui, Q. M., Huggins, R., Taylor, A. K., & Loesch, D. Z. (2007) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-006-0205-z · Cited by 377
Autistic behavior in children with fragile X syndrome: Prevalence, stability, and the impact of FMRP
Hatton, D. D., Sideris, J., Skinner, M., Mankowski, J., Bailey, D. B., Roberts, J., & Mirrett, P. (2006) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.31286 · Cited by 359
Self-citation
Cited by
Hagerman, R. J., Berry-Kravis, E., Hazlett, H. C., Bailey, D. B., Moine, H., Kooy, R. F., Tassone, F., Gantois, I., Sonenberg, N., Mandel, J. L., et al. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.65 · Cited by 838
Self-citationWhy are autism spectrum conditions more prevalent in males?
Baron-Cohen, S., Lombardo, M. V., Auyeung, B., Ashwin, E., Chakrabarti, B., & Knickmeyer, R. (2011) · PLoS Biology · doi:10.1371/journal.pbio.1001081 · Cited by 754
Clinical Genetic Testing for Patients With Autism Spectrum Disorders
Shen, Y., Dies, K. A., Holm, I. A., Bridgemohan, C., Sobeih, M. M., Caronna, E. B., Miller, K. J., Frazier, J. A., Silverstein, I., Picker, J., et al. (2010) · Pediatrics · doi:10.1542/peds.2009-1684 · Cited by 394
Cordeiro, L., Ballinger, E., Hagerman, R., & Hessl, D. (2011) · Journal of Neurodevelopmental Disorders · doi:10.1007/s11689-010-9067-y · Cited by 316
FMR1 CGG allele size and prevalence ascertained through newborn screening in the United States
Tassone, F., Iong, K. P., Tong, T.-H., Lo, J., Gane, L. W., Berry-Kravis, E., Nguyen, D., Mu, L. Y., Laffin, J., Bailey, D. B., et al. (2012) · Genome Medicine · doi:10.1186/gm401 · Cited by 315
Self-citationHagerman, R., & Hagerman, P. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70125-x · Cited by 313
Autism spectrum disorder in fragile X syndrome: cooccurring conditions and current treatment
Kaufmann, W. E., Kidd, S. A., Andrews, H. F., Budimirovic, D. B., Esler, A., Haas-Givler, B., Stackhouse, T., Riley, C., Peacock, G., Sherman, S. L., et al. (2017) · PEDIATRICS · doi:10.1542/peds.2016-1159f · Cited by 268
Fragile X syndrome: a review of associated medical problems
Kidd, S. A., Lachiewicz, A., Barbouth, D., Blitz, R. K., Delahunty, C., McBrien, D., Visootsak, J., & Berry-Kravis, E. (2014) · Pediatrics · doi:10.1542/peds.2013-4301 · Cited by 255
Fragile X and autism: intertwined at the molecular level leading to targeted treatments
Hagerman, R., Hoem, G., & Hagerman, P. (2010) · Molecular Autism · doi:10.1186/2040-2392-1-12 · Cited by 247
Modeling fragile X syndrome in the Fmr1 knockout mouse
Kazdoba, T. M., Leach, P. T., Silverman, J. L., & Crawley, J. N. (2014) · Intractable & Rare Diseases Research · doi:10.5582/irdr.2014.01024 · Cited by 241
Fragile X-Associated Neuropsychiatric Disorders (FXAND)
Hagerman, R. J., Protic, D., Rajaratnam, A., Salcedo-Arellano, M. J., Aydin, E. Y., & Schneider, A. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00564 · Cited by 204
Sinclair, D., Oranje, B., Razak, K. A., Siegel, S. J., & Schmid, S. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.05.029 · Cited by 198
“Between one quarter and one third of individuals with FXS are also diagnosed with ASD (Bailey et al., 2008; Rogers et al., 2001).”
CGG repeat in the FMR1 gene: size matters
Willemsen, R., Levenga, J., & Oostra, B. (2011) · Clinical Genetics · doi:10.1111/j.1399-0004.2011.01723.x · Cited by 184
Lozano, R., Rosero, C. A., & Hagerman, R. J. (2014) · Intractable & Rare Diseases Research · doi:10.5582/irdr.2014.01022 · Cited by 186
Fragile X: Leading the Way for Targeted Treatments in Autism
Wang, L. W., Berry-Kravis, E., & Hagerman, R. J. (2010) · Neurotherapeutics · doi:10.1016/j.nurt.2010.05.005 · Cited by 176
No Change in the Age of Diagnosis for Fragile X Syndrome: Findings From a National Parent Survey
Bailey, D. B., Raspa, M., Bishop, E., & Holiday, D. (2009) · Pediatrics · doi:10.1542/peds.2008-2992 · Cited by 175
Self-citationFragile X syndrome: a review of clinical and molecular diagnoses
Ciaccio, C., Fontana, L., Milani, D., Tabano, S., Miozzo, M., & Esposito, S. (2017) · Italian Journal of Pediatrics · doi:10.1186/s13052-017-0355-y · Cited by 160
McLennan, Y., Polussa, J., Tassone, F., & Hagerman, R. (2011) · Current Genomics · doi:10.2174/138920211795677886 · Cited by 160
Seizures in Fragile X Syndrome: Characteristics and Comorbid Diagnoses
Berry-Kravis, E., Raspa, M., Loggin-Hester, L., Bishop, E., Holiday, D., & Bailey, D. B. (2010) · American Journal on Intellectual and Developmental Disabilities · doi:10.1352/1944-7558-115.6.461 · Cited by 155
“…substantiated by the finding that higher percentages of individuals with fragile X syndrome were reported to have seizures across four older age categories and the 18% frequency of seizures observed in the National Fragile X Survey enrollees with fragile X syndrome over age 5 (Bailey et al., 2008).”
BackgroundInfluentialSelf-citationAdvances in understanding the molecular basis of FXTAS
Garcia-Arocena, D., & Hagerman, P. J. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq166 · Cited by 136
Pacey, L. K. K., Heximer, S. P., & Hampson, D. R. (2009) · Molecular Pharmacology · doi:10.1124/mol.109.056127 · Cited by 133
Metformin as targeted treatment in fragile X syndrome
Dy, A. B. C., Tassone, F., Eldeeb, M., Salcedo‐Arellano, M. J., Tartaglia, N., & Hagerman, R. (2018) · Clinical Genetics · doi:10.1111/cge.13039 · Cited by 124
Chonchaiya, W., Au, J., Schneider, A., Hessl, D., Harris, S. W., Laird, M., Mu, Y., Tassone, F., Nguyen, D. V., & Hagerman, R. J. (2012) · Human Genetics · doi:10.1007/s00439-011-1106-6 · Cited by 109
Berry-Kravis, E., Horrigan, J. P., Tartaglia, N., Hagerman, R., Kolevzon, A., Erickson, C. A., Hatti, S., Snape, M., Yaroshinsky, A., Stoms, G., et al. (2020) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2020.04.019 · Cited by 102
Klusek, J., Martin, G. E., & Losh, M. (2014) · Journal of Intellectual Disability Research · doi:10.1111/jir.12121 · Cited by 99
FMR1 premutation and full mutation molecular mechanisms related to autism
Hagerman, R., Au, J., & Hagerman, P. (2011) · Journal of Neurodevelopmental Disorders · doi:10.1007/s11689-011-9084-5 · Cited by 85
A prospective open-label study of aripiprazole in fragile X syndrome
Erickson, C. A., Stigler, K. A., Wink, L. K., Mullett, J. E., Kohn, A., Posey, D. J., & McDougle, C. J. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2194-7 · Cited by 69
Aripiprazole in Autism Spectrum Disorders and Fragile X Syndrome
Erickson, C. A., Stigler, K. A., Posey, D. J., & McDougle, C. J. (2010) · Neurotherapeutics · doi:10.1016/j.nurt.2010.04.001 · Cited by 65
Cornish, K., Cole, V., Longhi, E., Karmiloff-Smith, A., & Scerif, G. (2012) · American Journal on Intellectual and Developmental Disabilities · doi:10.1352/1944-7558-117.2.103 · Cited by 58
Brand, B. A., Blesson, A. E., & Smith-Hicks, C. L. (2021) · Brain Sciences · doi:10.3390/brainsci11070904 · Cited by 39
Wheeler, A. C., Miller, S., Wylie, A., & Edwards, A. (2018) · Frontiers in Public Health · doi:10.3389/fpubh.2018.00316 · Cited by 15
Winarni, T. I., Aishworiya, R., Culpepper, H., Zafarullah, M., Mendoza, G., Wilaisakditipakorn, T. J., Likhitweerawong, N., Law, J., Hagerman, R., & Tassone, F. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26072840 · Cited by 3
Metadata
- Authors
- Bailey, D. B., Raspa, M., Olmsted, M., & Holiday, D. B.
- Venue
- American Journal of Medical Genetics Part A
- Publisher
- Wiley
- Published
- 2008-06-20
- Volume
- 146A
- Issue
- 16
- Pages
- 2060-2069
- ISSN
- 1552-4825 (ISSN-L)
- 1552-4833
- OpenAlex
- W2038561863
- Cited by
- 446
- References
- 42
- FWCI
- 12.13
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.